CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 68 enrolled
Drug / intervention
D-cycloserine +1 moredrug
Likely dose
D-cycloserine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01086475
NCT01086475Phase 3Completed
CompareCT.gov

A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders

Indiana University·interventional·Posted Mar 15, 2010·Updated Apr 14, 2016

In Brief

A Phase 3 clinical trial evaluating D-cycloserine and Placebo for Autistic Disorder and 2 related conditions. Completed, enrolled 68 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2010
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.3 years ago

Interventions

D-cycloserinedrug

50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions

Placebodrug

Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions